Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 31;61(6):819–832. doi: 10.1007/s40262-022-01129-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig. 3 — Effect of extrinsic factors on the pharmacokinetics of (a) filgotinib and (b) its primary metabolite; effect of intrinsic factors on the pharmacokinetics of (c) filgotinib and (d) its primary metabolite (geometric mean of the point estimate with 90% CIs). Geometric mean ratio for AUC_∞ is shown when filgotinib was given as a single dose; geometric mean ratio of AUC_τ is shown when filgotinib was given as multiple doses. AUC_∞ area under the plasma concentration–time curve from time zero to infinity, AUC_τ area under the plasma concentration–time curve during a dosage interval (τ), CI confidence interval, C_max maximum (peak) plasma drug concentration, RI renal impairment

Fig. 3 — Effect of extrinsic factors on the pharmacokinetics of (a) filgotinib and (b) its primary metabolite; effect of intrinsic factors on the pharmacokinetics of (c) filgotinib and (d) its primary metabolite (geometric mean of the point estimate with 90% CIs). Geometric mean ratio for AUC_∞ is shown when filgotinib was given as a single dose; geometric mean ratio of AUC_τ is shown when filgotinib was given as multiple doses. AUC_∞ area under the plasma concentration–time curve from time zero to infinity, AUC_τ area under the plasma concentration–time curve during a dosage interval (τ), CI confidence interval, C_max maximum (peak) plasma drug concentration, RI renal impairment